BCM
AVEO

BlueCrest Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

BlueCrest Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,256
Closed -$75K – 1653
2018
Q3 		$75K Buy
+2,256
New +$58K ﹤0.01% 1416
2018
Q2 		– Sell
-17,231
Closed -$500K – 2008
2018
Q1 		$500K Buy
+17,231
New +$504K 0.02% 778

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlueCrest Capital Management's AVEO Position: Q4 2018 in Review

BlueCrest Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 2,256 shares — an estimated $75K sold.

BlueCrest Capital Management first reported a position in AVEO in Q1 2018 and held it in 2 quarters. The position peaked at $500K in Q1 2018. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

  • BlueCrest Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,256 AVEO Pharmaceuticals, Inc. shares in Q4 2018, an estimated $75K.
  • BlueCrest Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $500K in Q1 2018.
  • 99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.